Despite the growing list of reported candidate biomarkers, none has replaced the blood prostate-specific antigen (PSA) currently used as a biomarker for PCa screening despite its relatively low specificity and limited prognostic value (9, 10). The gene discussed is KLK3; the disease is posterior cortical atrophy.